Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy

Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial

(2017) Klemens Budde et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Histological and Extended Clinical Outcomes After ABO-Incompatible Renal Transplantation Without Splenectomy or Rituximab

(2017) Kevin V. Chow et al.   TRANSPLANTATION

Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial

(2017) Matthew R. Weir et al.   TRANSPLANTATION

Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation

(2016) Jin-yu Liu et al.   AMERICAN JOURNAL OF THERAPEUTICS

Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study

(2015) Klemens Budde et al.   CLINICAL NEPHROLOGY

Risk of Metabolic Complications in Kidney Transplantation After Conversion to mTOR Inhibitor: A Systematic Review and Meta-Analysis

(2014) N. Murakami et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study

(2014) K. Budde et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation

(2014) Lars Mjörnstedt et al.   TRANSPLANT INTERNATIONAL

A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care inde novokidney transplant recipients

(2013) Steven J. Chadban et al.   TRANSPLANT INTERNATIONAL

Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study

(2012) K. Budde et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation

(2012) L. Mjörnstedt et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36 months after transplantation

(2012) Markus Guba et al.   TRANSPLANT INTERNATIONAL

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

(2011) Klemens Budde et al.   LANCET

Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month Study

(2011) Hallvard Holdaas et al.   TRANSPLANTATION

Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal-Transplant Recipients

(2010) H. Tedesco Silva Jr. et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial

(2010) Matthew R. Weir et al.   KIDNEY INTERNATIONAL

Renal Function, Efficacy, and Safety of Sirolimus and Mycophenolate Mofetil After Short-Term Calcineurin Inhibitor-Based Quadruple Therapy in De Novo Renal Transplant Patients: One-Year Analysis of a Randomized Multicenter Trial

(2010) Markus Guba et al.   TRANSPLANTATION

Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study

(2009) Y. Lebranchu et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial

(2009) Francesco P. Schena et al.   TRANSPLANTATION

Minimization of Maintenance Immunosuppression Early After Renal Transplantation: An Interim Analysis

(2009) Frederike J. Bemelman et al.   TRANSPLANTATION

Renal Function Outcomes in Kidney Transplant Recipients After Conversion to Everolimus-Based Immunosuppression Regimen with CNI Reduction or Elimination

(2009) A. Cataneo-Dávila et al.   TRANSPLANTATION PROCEEDINGS